Objective: To assess superiority of acetyl-L-carnitine/riluzole (ALC) combination over riluzole alone on functional disability in patients with amyotrophic lateral sclerosis (ALS). Background ALS is a fatal motorneuron disease. Unlike riluzole, no disease-modifier drugs are available. ALC counteracts motor neuron death induced by toxic agents or deprivation of trophic factors and reduces disease progression in animal models. Design/Methods: Patients 40-70 years with definite or probable ALS, disease duration 6-24 months, self-supporting (ie, able to swallow, cut foods/handling utensils, and walk), and with forced vital capacity (FVC)>80% were enrolled in a pilot double-blind, placebo-controlled, parallel group trial and followed for...
OBJECTIVE: To determine whether valproic acid (VPA), a histone deacetylase inhibitor that showed ant...
Abstract Background Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that ca...
International audienceIntroduction: To date, riluzole and edaravone are the only two drugs that have...
Objective: To assess superiority of acetyl-L-carnitine/riluzole (ALC) combination over riluzole alon...
Our objective was to assess the effects of acetyl-L-carnitine (ALC) with riluzole on disability and ...
Our objective was to assess the effects of acetyl-L-carnitine (ALC) with riluzole on disability and ...
Background and purpose: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produce...
Background and purpose: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produce...
Riluzole is to date the only treatment that prolongs amyotrophic lateral sclerosis (ALS) survival. H...
Objective: To assess masitinib in the treatment of ALS. Methods: Double-blind study, randomly assign...
International audienceBackground: Rasagiline, a monoamine oxidase B inhibitor with neuroprotective p...
OBJECTIVE: To determine whether valproic acid (VPA), a histone deacetylase inhibitor that showed ant...
Abstract Background Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that ca...
International audienceIntroduction: To date, riluzole and edaravone are the only two drugs that have...
Objective: To assess superiority of acetyl-L-carnitine/riluzole (ALC) combination over riluzole alon...
Our objective was to assess the effects of acetyl-L-carnitine (ALC) with riluzole on disability and ...
Our objective was to assess the effects of acetyl-L-carnitine (ALC) with riluzole on disability and ...
Background and purpose: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produce...
Background and purpose: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produce...
Riluzole is to date the only treatment that prolongs amyotrophic lateral sclerosis (ALS) survival. H...
Objective: To assess masitinib in the treatment of ALS. Methods: Double-blind study, randomly assign...
International audienceBackground: Rasagiline, a monoamine oxidase B inhibitor with neuroprotective p...
OBJECTIVE: To determine whether valproic acid (VPA), a histone deacetylase inhibitor that showed ant...
Abstract Background Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that ca...
International audienceIntroduction: To date, riluzole and edaravone are the only two drugs that have...